Skip to main content

Table 3 Participants classified as sarcopenic or having the metabolic syndrome at baseline and 12 weeks

From: Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial

  Baseline Week 12 P*
Variable n % n %
Sarcopenia
 EXE 5 38.5 2 15.4 0.04
 NoEXE 9 47.4 10 52.6  
MetS
 EXE 6 50.0 6 50.0 0.18
 NoEXE 7 36.8 8 42.1  
MetS Suma
 EXE 2.8 1.4 2.8 1.5 0.54
 NoEXE 2.1 1.4 2.3 1.6  
  1. Data presented as number of participants, % of participants, except where indicated by a(mean ± standard deviation); P, significance level; EXE, exercise groups (TRAINPRO and TRAIN); NoEXE, non-exercise groups (PRO and STRETCH); MetS, metabolic syndrome
  2. *Analysis adjusted for baseline values, protein supplementation, body mass index and number of comorbidities